Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma
| Autor: | Robert S. Benjamin, Daniela Katz, Alexander J. Lazar, Vinod Ravi, Lianchun Xiao, Haeson Choi, Min S. Park, Wei-Lein Wang, Dejka M. Araujo, Piyaporn Boonsirikamchai |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Pathology
medicine.medical_specialty First line medicine.medical_treatment doxorubicin lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Choi Criteria Surgical oncology Medicine Doxorubicin myxoid liposarcoma 030304 developmental biology 0303 health sciences Myxoid liposarcoma Chemotherapy Ifosfamide business.industry ifosfamide Research Soft tissue sarcoma medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens 3. Good health Choi criteria Oncology 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | Clinical Sarcoma Research, Vol 2, Iss 1, p 2 (2012) Clinical Sarcoma Research |
| ISSN: | 2045-3329 |
| Popis: | Background Myxoid liposarcoma (MLS) is a soft tissue sarcoma with adipocytic differentiation characterized by a unique chromosome rearrangement, t(12;16)(q13;p11). The exact efficacy of chemotherapy in MLS has not been clearly established. Patients and methods We retrospectively analyzed the records of 37 histologically confirmed MLS patients who were treated at the University of Texas MD Anderson Cancer Center from January 2000 to December 2009 with doxorubicin 75-90 mg/m2 over 72 hours combined with ifosfamide 10 gm/m2 in the first-line setting. Response was assessed using RECIST and Choi criteria. The Kaplan-Meier method and log-rank test was used to estimate clinical outcomes. Results The median follow-up period was 50.1 months. The overall response rates were 43.2% using RECIST and 86.5% using the Choi criteria. The 5-year disease-free survival rate was 90% for patients with resectable tumors. Median time to progression and overall survival time for the advanced-disease group were 23 and 31.1 months, respectively. Conclusion Our study demonstrates that doxorubicin-ifosfamide combination therapy has a role in the treatment of MLS. The Choi criteria may be more sensitive in evaluating response to chemotherapy in MLS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink